An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment

Trial Profile

An Open Label, Multi-center Imatinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Imatinib Study and Are Judged by the Investigator to Benefit From Continued Imatinib Treatment

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 25 May 2017

At a glance

  • Drugs Imatinib (Primary)
  • Indications Chronic myeloid leukaemia; Gastrointestinal stromal tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
  • Most Recent Events

    • 09 Sep 2016 Planned End Date changed from 1 Oct 2024 to 1 Jun 2024.
    • 09 Sep 2016 Planned primary completion date changed from 1 Oct 2024 to 1 Jun 2024.
    • 07 Apr 2016 Planned End Date changed from 1 Sep 2023 to 1 Oct 2024 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top